Stéphane Bancel, Moderna CEO (Michael Brochstein/Sipa USA/Sipa via AP Images)
May 1, 2025 06:30 AM EDT
R&D
Pharma

Mod­er­na ex­pands ef­fort to rein in costs in an ‘un­cer­tain en­vi­ron­ment’

Max Bayer

Pharma Reporter

Mod­er­na is ex­pand­ing a cost con­trol pro­gram as it seeks to break even in the com­ing years, de­spite chal­lenges for vac­cine mak­ers from the Trump …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Hinge Health is go­ing pub­lic on Thurs­day at a $3B val­u­a­tion

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

FDA asks Covid vac­cine mak­ers to add more my­ocardi­tis da­ta to la­bels

Up­dat­ed: Eikon Ther­a­peu­tics cuts staff for the sec­ond time in less than two years

Al­tos Labs buys an­ti-ag­ing start­up Do­ri­an Ther­a­peu­tics

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times